Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066051 · ClinicalTrials.gov registry record · NA
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02066051: Completed NA study, sponsored by Mayo Clinic.
NCT02066051 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066051, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study was to see if Intense Pulsed Light (IPL) can be used safely and effectively to help treat dry eyes from ocular rosacea after chronic graft-versus-host disease (GVHD). Current treatment options for this disease are limited.
Interventions
- PROCEDURE Meibomian Gland Expression
- DEVICE IPL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02066051
The ClinicalTrials.gov registry entry for NCT02066051 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Meibomian Gland Expression is the first listed.
NCT02066051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02066051 about?
NCT02066051 is a clinical study titled "IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD". The purpose of this study was to see if Intense Pulsed Light (IPL) can be used safely and effectively to help treat dry eyes from ocular rosacea after chronic graft-versus-host disease (GVHD). Current treatment options for this disease are limited.
What is the current status of trial NCT02066051?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2013-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02066051?
The interventions under investigation include: Meibomian Gland Expression (PROCEDURE), IPL (DEVICE).
Who is sponsoring clinical trial NCT02066051?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.